oncology

How Reproducible are Preclinical Study Results?
How Reproducible are Preclinical Study Results?
Xtalks
preclinical study results
cancer
oncology
clinical trials
Flag link:
Upstart women’s oncology company in-licenses PhII PARP; Beijing biotech grabs $29M startup round
Upstart women’s oncology company in-licenses PhII PARP; Beijing biotech grabs $29M startup round
Endpoints
oncology
PARP inhibitors
2X Oncology
Eisai
2X-121
Jazz Pharmaceuticals
Flag link:
Cancer's Big Infrastructure Problem
Cancer's Big Infrastructure Problem
Forbes
cancer
oncology
personalized medicine
clinical trials
clinical trial data
Flag link:
A New Cancer Drug Helped Almost Everyone Who Took It. Almost. Here's What It Teaches Us
A New Cancer Drug Helped Almost Everyone Who Took It. Almost. Here's What It Teaches Us
Forbes
cancer
oncology
larotrectinib
Loxo Oncology
clinical trials
patients
Flag link:
Facts & Figures: Diversity in Oncology
Facts & Figures: Diversity in Oncology
ASCO.org
diversity
physicians
oncology
ASCO 2017
Flag link:
Why Novartis' Shah-Mehta chose a career in pharma sales
Why Novartis' Shah-Mehta chose a career in pharma sales
Medical Marketing and Media
Novartis
marketing
oncology
Flag link:
At big cancer meeting, a big question: Is the U.S. ‘losing its edge’
At big cancer meeting, a big question: Is the U.S. ‘losing its edge’
Stat
ASCO 2017
oncology
Flag link:
Report: Oncology costs increasing faster than before
Report: Oncology costs increasing faster than before
BioPharma Dive
oncology
QuintilesIMS
Flag link:
Sanofi beefs up cancer drug pipeline, paying cash hungry ImmunoGen $30M for full rights to oncology portfolio
Sanofi beefs up cancer drug pipeline, paying cash hungry ImmunoGen $30M for full rights to oncology portfolio
Endpoints
Sanofi
Immunogen
oncology
M&A
isatuximab
Multiple Myeloma
Flag link:
7 Areas to watch from the ASCO abstracts
7 Areas to watch from the ASCO abstracts
BioPharma Dive
ASCO 2017
oncology
Incyte
Merck
Eli Lilly
CAR-T
NewLink Genetics
Amgen
Roche
Kite Pharma
Juno Therapeutics
Flag link:
Here's How Much Teva Pharmaceutical Could Net From the Sale of Non-Core Assets
Here's How Much Teva Pharmaceutical Could Net From the Sale of Non-Core Assets
Motley Fool
Teva Pharmaceutical
M&A
Women's Health
oncology
Flag link:
AstraZeneca Shows That With Immune Cancer Drugs, No One Knows What's Next
AstraZeneca Shows That With Immune Cancer Drugs, No One Knows What's Next
Forbes
AstraZeneca
oncology
Imfinzi
Opdivo
Keytruda
Flag link:
Teva, still searching for 'world-class' CEO, officially puts women's health, cancer on the block
Teva, still searching for 'world-class' CEO, officially puts women's health, cancer on the block
Fierce Pharma
Teva Pharmaceutical
Pharma CEOs
M&A
Women's Health
oncology
Flag link:
3 Reasons Teva Pharmaceutical Industries Lost Another $520 Million in Market Value in April
3 Reasons Teva Pharmaceutical Industries Lost Another $520 Million in Market Value in April
Fierce Pharma
Teva Pharmaceutical
bribery
Women's Health
oncology
reorganization
Flag link:
UroToday.com, Leading Urology Reference Site, Launches a New Clinical Trials Portal
UroToday.com, Leading Urology Reference Site, Launches a New Clinical Trials Portal
CP Wire
urology
oncology
clinical trials
Flag link:
Cancer patients skipping medicines or delaying treatment due to high drug prices
Cancer patients skipping medicines or delaying treatment due to high drug prices
Stat
patients
oncology
cancer
drug pricing
Flag link:
UroToday.com, Leading Urology Reference Site, Launches a New Clinical Trials Portal
urology
oncology
clinical trials
website
Flag link:
Billionaire-backed Chi-Med declares PhIII success for pioneering cancer drug in China, seeking quick OK
Billionaire-backed Chi-Med declares PhIII success for pioneering cancer drug in China, seeking quick OK
Endpoints
Chi-Med
fruquintinib
oncology
cancer
China
Flag link:
Most new, high-priced cancer drugs don’t even extend life for 10 weeks
Most new, high-priced cancer drugs don’t even extend life for 10 weeks
ARS Technica, UK
cancer
oncology
Flag link:
Merck's DTC ad for Keytruda hints at more cancer brands turning to TV
Merck's DTC ad for Keytruda hints at more cancer brands turning to TV
Medical Marketing and Media
DTC advertising
Merck
Keytruda
drug ads
oncology
Flag link: